Bibliography
- Product information. Rocephin. Roche Laboratories: Nutley, New Jersey; 2007
- Adu A, Armour CL. Drug utilization review of the third generation of cephalosporins. Drugs 1995;50:423-39
- Peck P. FDA cites risks of ceftriaxone (rocephin) mixed with calcium. Medpage Today. Available from: http://wwwmedpagetodaycom/ProductAlert/Prescriptions/tb/6098 [Last accessed 27 February 2007]
- Important prescribing information. FDA MedWatch. Available from: http://wwwfdagov/medWatch/SAFETY/2007/rocephin_DHCP_june2007pdf [Last accessed 27 February 2007]
- Important clarification of prescribing information. FDA MedWatch. Available from: http://wwwfdagov/MEDWATCH/SAFETY/2007/Rocephin_HCP_august2007pdf [Last accessed 27 February 2007]
- Peck P. Ceftriaxone (rocephin) plus calcium warning extended to adults. Medpage Today. Available from: http://wwwmedpagetodaycom/Pediatrics/GeneralPediatrics/tb/6661 [Last accessed 27 February 2007]
- Traynor K. Roche clarifies ceftriaxone warnings. ASHP Health System Pharmacy. Available from: http://wwwashporg/s_ashp/article_newsasp?CID=167&DID=2024&id=21101 [Last accessed 27 February 2007]
- Moskovitz B. Clinical adverse effects during ceftriaxone therapy. Am J Med 1984;77:84-8
- Martin E. Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in children. Eur J Clin Microbiol 1983;2:509-15
- McCracken G, Siegel JD, Threlkeld N, Thomas M. Ceftriaxone pharmacokinetics in newborn infants. Antimicrob Agents Chemother 1983;23:341-3
- Mulhall A, de Louvois J, James J. Pharmacokinetics and safety of ceftriaxone in the neonate. Eur J Pediatr 1985;144:379-82
- Van Reempts P, Van Overmeire B, Mahieu LM, Vanacker KJ. Clinical experience with ceftriaxone treatment in the neonate. Chemotherapy 1995;41:316-22
- Bradley J, Ching DL, Wilson TA, et al. Once-daily ceftriaxone to complete therapy of uncomplicated group B streptococcal infection in neonates. A preliminary report. Clin Pediatr 1992;31:274-8
- Bradley J. Once-daily ceftriaxone in the outpatient treatment of paediatric infections. Chemotherapy 1991;37(Suppl 3):3-6
- Rae C, Fazio A, Rosales JP. Successful treatment of neonatal Citrobacter freundii meningitis with ceftriaxone. DICP 1991;25:27-9
- Wiese G. Treatment of neonatal sepsis with ceftriaxone/gentamicin and with azlocillin/gentamicin: a clinical comparison of efficacy and tolerability. Chemotherapy 1988;34:158-63
- James J, Mulhall A, de Louvois J. Ceftriaxone-clinical experience in the treatment of neonates. J Infect 1985;11:25-33
- Odio C. Cefotaxime for treatment of neonatal sepsis and meningitis. Diagn Microbiol Infect Dis 1995;22:111-7
- Broderson R, Robertson A. Ceftriaxone binding to human serum albumin: competition with bilirubin. Mol Pharmacol 1989;36:478-83
- Fink S, Karp W, Robertson A. Ceftriaxone effect on bilirubin-albumin binding. Pediatrics 1987;80:873-5
- Gulian J, Dalmasso C, Pontier F, Gonard V. Displacement effect of ceftriaxone on bilirubin bound to human serum albumin. Chemotherapy 1986;32:399-403
- Gulian J, Gonard V, Dalmasso C, Palix C. Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of ‘free’ bilirubin and erythrocyte-bound bilirubin. J Antimicrob Chemother 1987;19:823-9
- Gulian J, Dalmasso C, Gonard V. Interaction of beta-lactam antibiotics on bilirubin-albumin complex: comparison by three methods, total bilirubin, unbound bilirubin, and erythrocyte-bound bilirubin. Chemotherapy 1990;36:91-7
- Martin E, Fanconi S, Kalin P, et al. Ceftriaxone-bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr 1993;152:530-4
- Wadsworth S, Byungse S. In vitro displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycin in newborns. Antimicrob Agents Chemother 1988;32:1571-5
- Silverman W, Andersen DH, Blanc WA, Crozier DN. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 1956;18:614-25
- Odell G. Studies in kernicterus: the protein binding of bilirubin. J Clin Invest 1959;28:823-33
- Taketomo C, Hodding JH, Kraus DM. Pediatric dosage handbook. 13th edition. Hudson, Ohio; 2006
- Behrman R, Liegmans RM, Jenson HB. Nelson's textbook of pediatrics. Philadelphia: Saunders; 2000
- Johnson L, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr 2002;140:396-403
- Porter M, Dennis B. Hyperbilirubinemia in the term newborn. Am Fam Physician 2002;65:599-606
- Ip S, Chung M, Kulig J, et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004;114:e130-53
- Shiffman M, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterol 1990;99:1772-8
- Xia Y, Lambert KJ, Schteingart CD, et al. Concentrative biliary secretion of ceftriaxone. Inhibition of lipid secretion and precipitation of calcium ceftriaxone in bile. Gastroenterology 1990;99:454-65
- Acun C, Erdem L, Sogut A, et al. Ceftriaxone-induced biliary pseudolithiasis and urinary bladder sludge. Pediatr Int 2004;46:368-70
- Araz N, Okan V, Demirci M, Araz M. Pseudolithiasis due to ceftriaxone tretament for meningitis in children: report of 8 cases. Tohoku J Exp Med 2007;211:285-90
- Biner B, Oner N, Celtik C, et al. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound 2006;34:217-22
- Blais C, Duperval R. Biliary pseudolithiasis in a child associated with 2 days of ceftriaxone therapy. Pediatr Radiol 1994;24:218-9
- Bonioli E, Bellini C, Toma P. Pseudolithiasis and intractable hiccups in a boy receiving ceftriaxone. N Engl J Med 1994;331:1532
- Bonnet J, Abid L, Dabhar A, et al. Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children: a prospective study in 34 children. Eur J Pediatr Surg 2000;10:368-71
- Bor O, Dinleyici EC, Kebapci M, Aydogdu SD. Ceftriaxone-associated biliary sludge and psuedocholelithiasis during childhood: a prospective study. Pediatr Int 2004;46:322-4
- Ceran C, Oztoprak I, Cankorkmaz L, et al. Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients. Int J Antimicrob Agents 2005;25:256-9
- de Moor R, Egberts AC, Schroder CH. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr 1999;158:975-7
- Evliyaoglu C, Kizartici T, Bademci T, et al. Ceftriaxone-induced symptomatic pseudolithiasis mimicking ICP elevation. Zentralbl Neurochir 2005;66:92-4
- Herek O, Sariolu A, Kocer N, et al. Biliary pseudolithiasis in childhood: a case report. Eur J Pediatr Surg 1999;9:337-9
- Jacobs R. Ceftriaxone-associated cholecystitis. Pediatr Infect Dis J 1988;7:434-6
- Kim S, Gura KM, Puder M. Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis. Pediatr Surgery Int 2006;22:562-4
- Kong M, Chen CY. Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children. Changgeng Yi Xue Za Zhi 1996;19:50-4
- Lebovics E, Halata MS, Rosario JA, et al. Endoscopic management of ceftriaxone pseudolithiasis involving the common bile duct and gall bladder. Gastrointest Endosc 1994;40:246-8
- Onlen Y, Gali E, Incecik F, et al. Ceftriaxone-associated biliary sludge and pseudolithiasis in children. Infect Dis Clin Pract 2007;15:167-70
- Ozturk A, Kaya M, Zeyrek D, et al. Ultrasonographic findings in ceftriaxone: associated biliary sludge and pseudolithiasis in children. Acta Radiol 2005;46:112-6
- Palanduz A, Yalcin I, Tonguc E, et al. Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound 2000;28:166-8
- Papadopoulou F, Efremidis S, Karyda S, et al. Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr 1999;88:1352-5
- Prince J, Senac S, Melvin O. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child. Pediatr Radiol 2003;33:648-51
- Robertson F, Crombleholme TM, Barlow SE, et al. Ceftriaxone choledocholithiasis. Pediatrics 1996;98:133-5
- Rozmanic V, Banac S, Ivosevic D, Cace N. Biliary colic and sonographic evidence of pseudocholelithiasos 36 h after treatment with ceftriaxone. J Paediatr Child Health 2006;42:658-9
- Sahni P, Patel PJ, Kolawole TM, et al. Ultrasound of ceftriaxone-associated reversible cholelithiasis. Eur J Radiol 1994;18:142-5
- Schaad U, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 1988;2:1411-3
- Vega C, Quinby PM, Aspy CB. Hepato-biliary abnormalities secondary to ceftriaxone use: a case report. J Okla State Med Assoc 1999;92:432-4
- Wen H, Huang Y, Zheng G. Ceftriaxone-associated gallbladder pseudolithiasis: report of one case. Acta Paediatr Taiwan 2004;45:290-2
- Ravisha M, Godambe SV. Ceftriaxone induced cholestasis in a neonate: a case report. Indian J Med Sci 2004;58:73-4
- Martin E, Koup JR, Paravinci U, et al. Pharmacokinetics of ceftriaxone in neonates and infants with meningitis. J Pediatr 1984;105:475-81
- Hayton W, Stoeckel K. Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet 1986;11:76-86
- Falezza G, Picolli PL, Franchini M, et al. Ceftriaxone-induced hemolysis in an adult. Transfusion 2000;40:1543-5
- Lo G, Higginbottom P. Ceftriaxone induced hemolytic anemia. Transfusion 1993;33:S25
- Longo F, Hastier P, Buckley MJ, et al. Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone. Am J Gastroenterol 1998;93:836-7
- Seltsam A, Salama A. Ceftriaxone-induced immune hemolysis; two case reports and a concise review of the literature. Intensive Care Med 2000;26:1390-4
- Kapur G, Valentini R, Mattoo T, et al. Ceftriaxone induced hemolysis complicated by acute renal failure. Pediatr Blood Cancer 2006;50:139-42
- Famularo G, Polchi S, De Simone C. Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriaxone: a rare but potentially severe complication. Ann Ital Med Int 1999;14:202-4
- Zinberg J, Chernaik R, Coman E, et al. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol 1991;86:1251-4
- Cometta A, Gallot-Lavallee-Villars S, Iten A, et al. Incidence of gallbladder lithiasis after ceftriaxone treatment. J Antimicrob Chemother 1990;25:689-95
- Thomas M, Peat B, Lang SD. Neutropenia during therapy with ceftriaxone. NZ Med J 1985;98:23-4
- Grossjohann B, Eichler P, Greinacher A, et al. Ceftriaxone causes drug-induced thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion 2004;44:1033-40
- Zimmerman A, Katona BG, Jodhka JS, Williams RB. Ceftriaxone-induced acute pancreatitis. Ann Pharmacother 1993;27:36-7
- Rapp R, Kuhn R. Clinical pharmaceutics and calcium ceftriaxone. Ann Pharmacother 2007;41:2072
- Gin A, Wheaton H, Dalton B. Clinical pharmaceutics and calcium-ceftriaxone. Ann Pharmacother 2008;42:450-1
- Cappareli E, Hochwald C, Rasmussen M, et al. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother 2005;49:2760-6